Islet Cell Transplantation in Patients With Type I Diabetes With Previous Kidney Transplantation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

14 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-03-31

Study Completion Date

2016-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This single center phase 2 clinical trial, is designed for confirming the efficacy and safety of sequential islet allotransplantation with steroid free immunosuppression in patients with previous kidney transplantation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Kidney Alone Versus Islet-After-Kidney in Type 1 Diabetic Kidney Transplant Recipient.

NCT05662267

type1diabetes Renal Failure End Stage Renal Disease

UNKNOWN

Islet Transplantation in Type 1 Diabetic Recipients of Kidney Transplants

NCT00288977

Diabetes Kidney Transplantation

COMPLETED NA

Islet Cell Transplantation in Patients With Type I Diabetes With Previous Kidney Transplantation

NCT00315588

Diabetes Mellitus, Type 1

COMPLETED PHASE2

Pancreatic Islet Cell Transplantation After Kidney Transplantation - A Novel Approach to Immunosupression

NCT03047200

Islet Cell Transplantation Type 1 Diabetes

WITHDRAWN PHASE1

Study of Islet Transplantation in Type 1 Diabetic Kidney Transplant Recipients

NCT00888628

Diabetes Mellitus, Type I

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The beneficial effects of glycemic control on both survival and function of transplanted kidneys in patients with type 1 diabetes mellitus have been recognized.

The purpose of this study is to reverse hyperglycemia and insulin dependency, by islet cell transplantation, in patients with type 1 diabetes mellitus who have a stable kidney allograft.

The study primary efficacy endpoint is graft survival defined as insulin independence and HbA1c \< 8% at 1 year post first transplant. Secondary outcomes are graft function and metabolic control

The immunosuppression protocol for the kidney graft was converted to sirolimus+tacrolimus regimen 6 months before islet transplantation to exclude negative effects on kidney graft function.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Immunosuppression Type 1 Diabetes Organ Transplantation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Islet transplantation

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

islet transplantation

Islet transplantation

Group Type EXPERIMENTAL

islet transplantation

Intervention Type PROCEDURE

Islet transplantation consisted of up to three sequential fresh islet infusions within three months. Access to the portal vein was gained under general anesthesia by percutaneous catheterisation of a peripheral portal branch under ultrasound guidance or by surgical catheterisation of a small mesenteric vein.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

islet transplantation

Islet transplantation consisted of up to three sequential fresh islet infusions within three months. Access to the portal vein was gained under general anesthesia by percutaneous catheterisation of a peripheral portal branch under ultrasound guidance or by surgical catheterisation of a small mesenteric vein.

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

surgical catheterisation percutaneous catheterisation

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Type 1 diabetes mellitus. Documentation of negative basal and stimulated C-peptide and diagnosis of diabetes for at least 5 years.
* Recipient of renal transplant with good function (creatinine clearance \>/=60 ml/min)
* Stable immunosuppression consisting of any combination of sirolimus, tacrolimus for at least 6 months, without major complications
* Ability to give informed consent.
* Age greater than or equal to 18 years or less than or equal to 65 years
* No evidence of liver disease (liver enzymes \< twice the upper limit of normal)

Exclusion Criteria

* Age below 18 years and above 65 years
* Significant cardiovascular disease, including non-correctable coronary artery disease and/or recent myocardial infarction(within last 12 months); extensive peripheral vascular disease not correctable by surgery, unstable angina
* Untreated proliferative retinopathy.
* Recent Cerebrovascular accident (within last 12 months)
* Recent unresolved acute infection, or chronic infection, including tuberculosis, HIV, HBV, HCV, CMV or positive skin test for TB
* Any history of malignancy, except squamous or basal skin cancer or in situ cancer of the cervix.
* History of non-compliance, or inability to demonstrate capacity to comply with strict blood glycemic control and insulin pump therapy.
* Psychiatric illness that is untreated, or likely to interfere significantly with transplantation despite treatment.
* Pregnant women, women intending future pregnancy, women of reproductive potential who are unable or unwilling to follow effective contraceptive measures for the duration of immunosuppressive therapy
* Fasting C-peptide \> 0.2 ng/ml
* Creatinine \> 25mg/l
* Alkaline phosphatase, total bilirubin, Alanine Aminotransferase (ALT)or Aspartate Aminotransferase (AST) \> twice the upper limit of normal
* Significant liver disease (elevation of liver enzymes \> twice the upper limit of normal for each of ALT and AST, liver masses including portal vein thrombosis, evidence of portal hypertension, or significant, untreated gallbladder disease (i.e., gallstones).

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No